Montes Claros

Montes Claros is where Brazil manufactures medicines it cannot afford to deliver late. IBGE's latest estimate puts the city at 437,601 residents, yet Novo Nordisk alone committed R$6.4 billion ($1.1 billion) in April 2025 to expand injectable-drug production there.

The city sits 686 metres above sea level in north Minas Gerais and is usually described as the commercial capital of a dry inland region. That is true, but it hides the city's real edge. Montes Claros works as a quality-controlled production node built on logistics. The municipal government still describes it as Brazil's second-largest highway junction, tied into BR-135, BR-365, BR-251, and BR-122. The same local narrative traces the industrial base back to SUDENE incentives that pulled manufacturers inland. A municipal note says seven medium and large pharmaceutical companies now operate in the city. Novo Nordisk's latest expansion adds new aseptic processes, a warehouse, and a quality-control lab, with 600 permanent jobs once the project is completed in 2028.

That is the Wikipedia gap. Montes Claros is not mainly important because it serves northern Minas. It matters because it gives Brazilian and global drugmakers a rare inland mix of road access, industrial land, utility capacity, and trained labor. Path dependence explains the cluster: once highways, incentives, suppliers, and technical know-how accumulated, the next regulated manufacturer had a reason to choose the same map pin. Niche construction explains the rest. The city and state kept shaping the habitat for pharmaceutical production rather than waiting for chance to do it. Mutualism then locks the system in place. Drugmakers need a city that can move inputs and finished medicines without coastal congestion; the city needs employers whose wages and tax base justify more infrastructure and specialist training.

Biologically, Montes Claros behaves like a termite mound. Termite mounds matter because they hold airflow, temperature, and traffic inside a narrow operating range that keeps production stable in a harsh environment. Montes Claros does the urban version for pharmaceuticals: it turns a hot inland junction into a place where precision manufacturing can keep running.